

SUPPLEMENTAL FIGURE LEGENDS

Figure S1. Interaction of Macrophages with Apoptotic Cells Leads to an Increase in Drp1, Which Promotes Efferocytosis, Related to Figures 1 and 2.

(A) Cre^{-/-} and Cre^{+/-} bone marrow-derived macrophages were rendered apoptotic by treatment with 35 µg/ml 7-ketocholesterol and then incubated with WT bone marrow-derived macrophages at a ratio of 10:1 for 45 minutes. The unengulfed ACs were removed by rinsing, and whole cell lysates were immunoblotted for Drp1 and β-actin. The bar graph shows densitometric quantification of immunoblots normalized to β-actin (n=3 biological replicates).

(B) Cre^{-/-} and Cre^{+/-} peritoneal macrophages were assayed for *Drp1* mRNA relative to *Actb* by RT-QPCR (n=3 biological replicates).

(C) Total cells lysates of Cre^{-/-} and Cre^{+/-}-peritoneal and bone marrow (BM)-derived macrophages were immunoblotted for Drp1 and two mitochondrial proteins, PDH1α and VDAC1.

(D) Cre^{-/-} and Cre^{+/-} bone marrow-derived macrophages were incubated with or without apoptotic Jurkat cells for 45 minutes, and then lysates were immunoblotted for Drp1.

(E) Cre^{-/-} and Cre^{+/-} peritoneal macrophages were immunostained using antibodies against Drp1 (green) and the mitochondria marker cytochrome C oxidase IV (COX IV) and viewed by confocal microscopy. Bar, 1 µm.

(F) Bone marrow-derived macrophages were treated for 30 min with 1 µg/ml actinomycin D or 10 µg/ml cycloheximide then incubated with or without apoptotic Jurkat cells for 45 minutes. Lysates were immunoblotted for Drp1 and β-actin. The bar graph shows densitometric quantification of immunoblots normalized to β-actin (n=4 biological replicates).

(G) CypHer5E-labeled apoptotic Jurkat cells were incubated with PKH67-labeled macrophages at 10:1 ratio for 45 minutes. The unengulfed ACs were removed by rinsing, and the macrophages were detached from the plate for flow cytometric analysis

of CypHer5E⁺ PKH67⁺ cells, which reflects efferocytosis. Representative contour plots and quantified data are shown (n=3 biological replicates).

(H) Macrophages were treated with 10 μ M MDIVI-1 or vehicle control, and then the cells were incubated with PKH26-labeled apoptotic Jurkat cells for 1 hour at a 10:1 AC:macrophage ratio (left) or for 2 hours at a 5:1 AC:macrophage ratio (right). Efferocytosis was measured as the total percent of macrophages positive for PKH67-labeled ACs (n=4 biological replicates).

Figure S2. Drp1-Deficient Macrophages Differentiate Normally and Show Expected Patterns of Polarization to Stimuli, and Effect of MDIVI-1 on Mitochondrial Length, Related to Figures 1 and 2.

(A) Macrophages differentiated from bone marrow cells of Cre^{-/-} and Cre^{+/-} mice were analyzed by flow cytometry for cell-surface F4/80, CD68, and Fc γ RI. Average MFI per macrophage is shown (n=3 biological replicates)

(B and C) Cre^{-/-} and Cre^{+/-} bone marrow-derived macrophages were treated with LPS and IFN γ or with IL-4 and then assayed for *Nos2*, *Tnfa*, *Il6*, *Arg1*, *Mrc1*, and *Retnla* mRNA by RT-qPCR, with normalization to *36B4* (n=3 biological replicates).

(D) Macrophages were treated with vehicle control or 10 μ M MDIVI-1 followed by incubation with PKH67-labeled apoptotic Jurkat cells for 45 minutes at a 5:1 AC:macrophage ratio. Unengulfed cells were rinsed away, and, after a 2-hour incubation period, the macrophages were labeled with MitoTracker Red FM and incubated for 45 minutes with CellVue Claret-labeled ACs at a 5:1 AC:macrophage ratio. Macrophages that had not engulfed an AC or engulfed 2 ACs were visualized by confocal microscopy and quantified for average mitochondrial length (n=3 biological replicates with 10 cells per treatment group quantified).

(E) Vehicle-treated Cre^{-/-} and Cre^{+/-} macrophages or MDIVI-1-treated Cre^{+/-} macrophages were subjected to the two-stage efferocytosis assay described in Figure 2C (n=4 biological replicates).

For all panels, values are mean + S.E.M.; *p < 0.05; n.s., not significant.

Figure S3. Macrophages with Impaired Mitochondrial Fission Have a Defect in Phagosome Sealing, Delayed Phagosome Acidification, and Defects in Large Particle Internalization, Related to Figures 3 and 4.

(A) Macrophages transfected with scrambled RNA or *Mff* siRNA were incubated with PKH67-labeled apoptotic Jurkat cells and MitoTracker Red FM for 45 minutes at a 5:1 AC:macrophage ratio. Macrophages that had or had not engulfed an AC (AC⁺, AC⁻) were visualized by confocal microscopy. Mean mitochondrial length was measured in 0.5 μ m z-sections in at least 10 cells per group across four biological replicates (n=3 with \geq 10 cells quantified per group). Also shown is an immunoblot of *Mff* in ScrRNA- and *Mff* siRNA-treated macrophages.

(B) Macrophages treated with ScrRNA or *Mff* siRNA were subjected to the two-stage efferocytosis assay described in Figure 2C.

(C) Macrophages treated with ScrRNA or *Mfn1* siRNA were immunoblotted for *Mfn1*, *Drp1*, and β -actin (n=3 biological replicates).

(D) Macrophages treated with ScrRNA, *Drp1* siRNA, or *Mfn1* siRNA were immunostained using an antibody against the mitochondria marker, ATP5A, and viewed by confocal microscopy. Bar, 1 μ m.

(E) Macrophages treated with ScrRNA, *Mfn1* siRNA, or *Drp1* siRNA were incubated for 1 hour with PKH67-labeled apoptotic Jurkat cells at a 10:1 AC:macrophage ratio and then efferocytosis was measured. The data are quantified as percent of macrophages positive for PKH67-labeled ACs (n=3 biological replicates).

(F) Macrophages treated with ScrRNA or *Mff* siRNA were subjected to the phagosome sealing assay after 45 minutes of incubation with ACs, as described in Figure 3 (n=4 biological replicates).

(G) Images from the time-lapse fluorescence microscopy experiment in Figure 3B examining time to CypHer5E positivity. Arrows in 0-min images show the AC being monitored. Bar, 5 μ m.

(H) *Cre*^{-/-} and *Cre*^{+/-} macrophages were incubated for 16 hours with dual-labeled rhodamine and fluorescein dextran to label lysosomes. Lysosomal pH was determined

by analyzing the fluorescein/rhodamine ratio (n=3 biological replicates with 30 cells per group quantified per experiment).

(I) Cre^{-/-} and Cre^{+/-} macrophages were subjected to the two-stage phagocytosis assay described in Figure 2C, using biotinylated versions of the indicated particles instead of biotinylated ACs (n=3 biological replicates).

Values are mean \pm S.E.M.; *p < 0.05; n.s., not significant.

Figure S4. Drp1-Deficient Macrophages Have Defects in AC Corpse Degradation and Phagosomal ROS, Quantification of ATP, and Illustrative Images of GCaMP6f Fluorescence Over Time, Related to Figures 4 and 5.

(A) Time-lapse confocal fluorescence microscopy of Cre^{-/-} and Cre^{+/-} macrophages incubated with apoptotic PMNs labeled with CypHer5E. Time to AC fragmentation was quantified as the time interval between the first frame in which the AC became CypHer5E + (t = 0 minutes) and the frame in which there was the first evidence of fragmentation of the CypHer5E signal (arrows). The time interval between each frame was ~3.57 minutes, some of which are displayed here. Bar, 10 μ m. The bar graph shows the mean \pm S.E.M., *p < 0.0001 (n = 15 cells per group).

(B) Cre^{-/-} and Cre^{+/-} macrophages were treated with 200 nM rapamycin (Rap) or vehicle control (Veh) for 18 hours. The cells were then fixed with 2% paraformaldehyde, permeabilized with digitonin, and immunostained for LC3. Fluorescence microscopic analysis was conducted to quantify the average number of LC3+ punctae (red spots) per cell (n=200 cells per group).

(C) Cre^{-/-} and Cre^{+/-} macrophages were incubated for 45 minutes with H2DCFDA-labeled apoptotic Jurkat cells that were loaded with the oxidant, TBHP (50 μ M), or vehicle control. Unengulfed ACs were then removed by rinsing, and the macrophages were then assayed for H2DCFDA fluorescence as a measure of ROS (n=3 biological replicates).

For panels B-C, values are mean \pm S.E.M.; *p < 0.05; n.s., not significant.

(D) Cre^{-/-} and Cre^{+/-} macrophages were incubated for 45 minutes under control conditions (no ACs) or with ACs, and relative ATP levels were quantified using an ATP fluorescence assay (n=3 technical replicates).

(E-G) Images from the time-lapse fluorescence microscopy experiment in Figure 5A-B examining Cyto- and Mito-GCaMP6f fluorescence intensity over time in AC⁻ and AC⁺ Cre^{-/-} and Cre^{+/-} macrophages; and images and quantified data for a similar experiment using ER-GCaMP6f-150 (n=3 cells for AC⁻ macrophages and n=10 cells for AC⁺ macrophages, with 2 plates of cells examined for each condition; values are mean ± S.E.M, *p < 0.05 for the two AC⁺ groups relative to the two AC⁻ groups, with no significant difference between the Cre^{-/-} and Cre^{+/-} groups). Bars, 10 μm.

Figure S5. Control Experiments Related Calcium Dynamics and Lysosome Acidification and Summary of Pathway Related to Figures 5 and 6.

(A) Wildtype macrophages were treated with 5 μM BAPTA-AM, and membrane-bound LC3 MFI was quantified by flow cytometry as in Figure 4C (n=3 biological replicates).

(B) Cre^{-/-} and Cre^{+/-} macrophages were incubated with 2 μM ionomycin (Iono) or vehicle control (Veh), and membrane-bound LC3 MFI was quantified by flow cytometry as in Figure 4C (n=4 biological replicates).

(C) Immunoblot of MCU1 and β-actin from macrophages incubated for 45 minutes without or with apoptotic Jurkat cells (ACs) (n =3 biological replicates).

(D) Cre^{-/-} and Cre^{+/-} macrophages were transfected with scrambled RNA or *Mcu* siRNA and then incubated for 45 minutes with PKH67-labeled apoptotic Jurkat cells and MitoTracker Red FM at a 5:1 AC:macrophage ratio. Mitochondrial length was length measured as in Figure 1 (n=10 cells analyzed per group).

(E) WT macrophages were treated with 1 μM bafilomycin (Baf) or vehicle control (Veh), incubated with PKH67-labeled ACs, and then assayed for mitochondrial length in macrophages containing or not containing ACs (n=3 biological replicates).

(F) Control and bafilomycin-treated macrophages were incubated with biotinylated ACs for the indicated times and then subjected to the phagosome sealing assay described in Figure 3 (n=3 replicates for each time point).

For all panels, values are mean \pm S.E.M.; * $p < 0.05$; n.s, not significant.

(G) Proposed model linking mitochondrial fission in macrophages engaging an AC to high-burden efferocytosis.

Figure S6. Quantification of Apoptotic Cells and Cytokine mRNAs in the Thymuses of Dexamethasone-Treated Mice and Validation of *Mcu*^{-/-} and MDIVI-1-Treated Mice, Related to Figure 7.

(A) Representative images of thymuses from Cre^{-/-} and Cre^{+/-} mice 18 hours after i.p. injection of PBS or 250 μ g dexamethasone. Bar, 1 mm.

(B) Thymocytes from Cre^{-/-} and Cre^{+/-} mice were treated with PBS or 100 μ M dexamethasone for 2 hours then stained with Annexin V and analyzed for the percentage of annexin V⁺ cells by flow cytometry (n=4 biological replicates per group).

(C) The thymuses of dexamethasone-treated Cre^{-/-} and Cre^{+/-} mice were assayed for the indicated mRNAs by RT-qPCR and expressed as fold-change relative to the Cre^{-/-} value (n=4 mice per group).

(D) The thymuses of dexamethasone-treated Cre^{-/-} and Cre^{+/-} mice were surface-immunostained for F4/80 and assayed for F4/80⁺ cells by flow cytometry (n=8 mice per group).

(E) Irradiated WT CD1 mice were transplanted with bone marrow from WT CD1 mice or *Mcu*^{-/-} mice on the CD1 background. After 6 weeks, the mice were sacrificed, and spleen lysates were immunoblotted for MCU and β -actin.

(F) Cre^{-/-} and Cre^{+/-} mice were injected i.p. every 12 hours for 3 treatments with 20 mg/kg MDIVI-1 or vehicle control. Macrophages were isolated from the thymuses of the mice in (C) and then fixed, immunostained stained for COXIV, and viewed by confocal fluorescence microscopy. Bar, 5 μ m. Average mitochondrial length was measured in \geq 10 cells per group across three biological replicates.

(G) Thymocytes from Cre^{-/-} mice were incubated for 2 hours with 100 μ M dexamethasone or vehicle control with or without 10 μ M MDIVI-1. The cells were then

stained with annexin V and analyzed for the percentage of annexin V⁺ cells by flow cytometry (n=3 biological replicates).

For all panels, values are mean ± S.E.M.; *p < 0.05; n.s., not significant.

Figure S7. Systemic Parameters in WD-Fed *Ldlr*^{-/-} Mice With or Without Myeloid Drp1 Deficiency, Related to Figure 7.

(A) Aortic smooth muscle cells isolated from Cre^{-/-} and Cre^{+/-} mice were assayed for *Drp1* mRNA relative to *Actb* by RT-QPCR (n=3 biological replicates).

(B-F) Body weight, fasting blood glucose, plasma cholesterol, triglyceride levels, and plasma lipoprotein profile from 12-week WD-fed *Drp1*^{fl/fl} *Lysmcre*^{+/-} (Cre^{-/-}) and *Drp1*^{fl/fl} *Lysmcre*^{+/-} (Cre^{+/-}) mice on the *Ldlr*^{-/-} (LDLR-KO) background.

(G) Aortic root cross-sections of 12-week WD-fed mice were quantified for total lesion area and immunostained for Mac3, followed by analysis of Mac3⁺ cells/section (n=12-14 mice per group)..

(H) Peritoneal macrophages from Cre^{-/-} and Cre^{+/-} mice were treated for 24 hours with vehicle (Veh), 50 µg/ml oxidized LDL (oxLDL), or 35 µg/ml 7-ketocholesterol (7-KC).

The cells were then stained with Annexin V and analyzed for the percentage of annexin V⁺ cells by flow cytometry (n=3 replicates per group).

For all panels, values are mean ± S.E.M.; *p < 0.05; n.s., not significant.